Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients

European Journal of Endocrinology

Volumn 158, Issue 1, 2008, Pages 47-52

  Akalin, Aysen ^a   Alatas, Ozkan ^a   Colak, Omer ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLUCOSE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; LIPID; SULFONYLUREA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC HYPERTENSION; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FIBRINOGEN BLOOD LEVEL; GLYCEMIC CONTROL; HOMOCYSTEINE BLOOD LEVEL; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FIBRINOGEN; HOMOCYSTEINE; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY FUNCTION TESTS; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38949091792     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0470     Document Type: Article

References (38)

1. Audelin MC & Genest J, Jr. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 2001 159 497-511.
2. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Jr & Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999 100 1134-1146.
3. Najemnik C, Sinzinger H & Kritz H. Endothelial dysfunction, atherosclerosis and diabetes. Acta Medica Austriaca 1999 26 148-153.
4. Blake GJ & Ridker PM. Novel clinical markers of vascular wall inflammation. Circulation Research 2001 89 763-771.
5. Farmer JA & Torre-Amione G. Atherosclerosis and inflammation. Current Atherosclerosis Reports 2002 4 92-98.
6. Eriksen G, Liestol K, Bjornholt JV, Stormorken H, Thaulow E & Eriksen J. Eritrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. European Heart Journal 2000 21 1614-1620.
7. Folsom AR, Pankow JS, Russell PT, Arnett DK, Peacock JM, Hong Y, Djousse L, Eckfeldt JH & Investigators of the NHLBI Family Heart Study. Association of C-reactive protein with markers of prevalent atherosclerotic disease. American Journal of Cardiology 2001 89 112-117.
8. Weintraub WS & Harrison DG. C-reactive protein, inflammation and atherosclerosis: do we really understand it yet? European Heart Journal 2000 21 958-960.
9. Colhoun HM, Rubens ME, Schalkwijk C & Stehouwer CDA. C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification. Diabetes Care 2002 25 1813-1817.
10. Haidari M, Javadi E, Sadeghi B, Hajilooi M & Ghanbili J. Evaluation of C-reactive protein, a risk factor for stable coronary artery disease. Clinical Biochemistry 2001 33 309-315.
11. Klein RI, Hunter S, Jenkins AJ, Zheng D, Semler AJ, Clore J, Garvey WT & The DCCT/EDIC Study Group. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes. Diabetes Care 2003 26 1439-1448.
12. Pepys MB & Hirschfield GM. C-reactive protein and atherotrombosis. Italian Heart Journal 2001 2 196-199.
13. Elkind MS, Cheng J, Boden-Albala B, Rundek T, Thomas J, Chen H, Rabbani LE & Sacco RL. Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. Stroke 2002 33 31-38.
14. Jager A, Van Hinsberg VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM & Stehouwer CD. Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 3071-3078.
15. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ & Parving HH. Increased urinary albumin excretion, endothelial dysfunction and chronic low-grade inflammation in type 2 diabetes:progressive, interrelated, and independently associated with risk of death. Diabetes 2002 51 1157-1165.
16. Ceriello A, Taboga C, Giacomello R, Falleti E, DeStasio G, Motz E, Lizzio S, Gonano F & Bartoli E. Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes 1994 43 430-432.
17. Papanicolaou DA, Wilder R, Manolagas SC & Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Annals of Internal Medicine 1998 128 127-137.
18. Fonseca V, Guba SC & Fink LM. Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endocrine Reviews 1999 20 738-779.
19. Hofmann MA, Kohl B, Zumbach MS, Borcea V, Bierhaus A, Henkels M, Amiral J, Schmidt AM, Fiehn W, Ziegler R, Wahl P & Nawroth PP. Hyperhomocysteinemia and endothelial dysfunction in IDDM. Diabetes Care 1998 21 841-847.
20. Okada E, Oida K, Tada H, Asazuma K, Eguchi K, Tohda G, Kosaka S, Takahashi S & Miyamori I. Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 1999 22 484-490.
21. Buysschaert M, Dramais AS, Wallemacq PE & Hermans MP. Hyperhomocysteinemia in type 2 diabetes. Diabetes Care 2000 23 1816-1822.
22. Koning ABL, Werstuck GH, Zhou J & Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clinical Biochemistry 2003 36 431-441.
23. Knect P, Reunanen A, Alfthan G, Heliovaara M, Rissanen H, Marniemi J & Aroma A. Hyperhomocysteinemia: a risk factor or a consequence of coronary heart disease? Archives of Internal Medicine 2001 161 1589-1594.
24. Abdella NA, Mojiminiyi OA, Akanji AO & Moussa MA. Associations of plasma homocysteine concentration in subjects with type 2 diabetes mellitus. Acta Diabetologica 2002 39 183-190.
25. Mendall MA, Patel P, Balam L, Strachan D & Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996 312 1061-1065.
26. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, Stehouwer CD & The Eurodiab Prospective Complications Study Group. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes. Diabetes Care 2003 26 2165-2173.
27. Festa A, D'Agostino R, Howard G, Jr, Mykkanen L, Tracy RP & Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney International 2000 58 1703-1710.
28. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. Journal of Thrombosis and Haemostasis 2005 3 1646-1654.
29. Aso Y, Yoshida N, Okumura K, Wakabayashi S, Matsumoto R, Takebayashi K & Inukai T. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clinica Chimica Acta 2004 348 139-145.
30. Becker A, Kostense PJ, Bos G, Heine RJ, Dekker JM, Nijpels G, Bouter LM & Stehouwer CDA. Hyperhomocysteinaemia is associated with coronary events in type 2 diabetes. Journal of Internal Medicine 2003 252 293-300.
31. Kalantarinia K, Awad AS & Siragy HM. Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats. Kidney International 2003 64 1208-1213.
32. Araki A, Hosoi T, Orimo H & Ito H. Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes. Metabolism: Clinical and Experimental 2005 54 809-814.
33. Gori AM, Corsi AM, Fedi S, Gazini A, Sofi F, Bartali B, Bandinelli S, Gensini GF, Abbate R & Ferruci L. A proinflammatory state is associated with hyperhomocysteinemia in the elderly. American Journal of Clinical Nutrition 2005 82 335-341.
34. Jonasson T, Ohlin AK, Gottsater A, Hultberg B & Ohlin H. Plasma homocysteine and markers for oxidative stress and inflammation in patients with coronary artery disease - a prospective randomized study of vitamin supplementation. Clinical Chemistry and Laboratory Medicine 2005 43 628-634.
35. Durga J, van Tits LJ, Schouten EG, Kok FJ & Verhoef P. Effect of lowering homocysteine levels on inflammatory markers: a randomized controlled trial. Archives of Internal Medicine 2005 165 1388-1394.
36. Suliman ME, Stenvinkel P, Qureshi R, Barany P, Heimburger O, Anderstam B, Alvestrand A & Lindholm B. Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. American Journal of Kidney Diseases 2004 3 455-465.
37. Becker A, van Hinsbergh VWM, Kostense PJ, Jager A, Dekker JM, Nijpels G, Heine RJ, Bouter LM & Stehouwer CDA. Serum homocysteine is weakly associated with von Willebrand factor and soluble vascular adhesion molecule I, but not with C-reactive protein in type 2 diabetic and non-diabetic subjects - The Hoorn Study. European Journal of Clinical Investigation 2000 30 763-770.
38. Mezzano D, Pais EO, Aranda E, Panes O, Downey P, Ortiz M, Tagle R, Gonzales F, Quirga T, Caceres MS, Leighton F & Preira J. Inflammation, not hyperhomocysteinemia, is related to oxidative stres and hemostatic and endothelial dysfunction in uremia. Kidney International 2001 60 1844-1850.